Venclexta for CMML – pro
It is s under study or the subject of ongoing clinical trials for the requested indication: A Study Evaluating Venetoclax in Combination With Azacitidine in Subjects With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS),NCT02942290.
L. Dembeck, A Study Evaluating Venetoclax in Combination With Azacitidine in Subjects With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS
Coston T, Pophali P, Vallapureddy R, et al. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients [published online April 9, 2019]. Am J Hematol. doi:10.1002/ajh.25488